ResMed Inc. (NYSE:RMD) is scheduled to announce its earnings results after the market closes on Tuesday, August 1st. Analysts expect the company to announce earnings of $0.75 per share for the quarter.
ResMed (NYSE:RMD) last released its earnings results on Thursday, April 27th. The medical equipment provider reported $0.71 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.70 by $0.01. The company had revenue of $514.20 million during the quarter, compared to analyst estimates of $525.84 million. ResMed had a net margin of 15.96% and a return on equity of 22.53%. The firm’s quarterly revenue was up 13.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.68 EPS. On average, analysts expect ResMed to post $2.8 EPS for the current fiscal year and $3.12 EPS for the next fiscal year.
Shares of ResMed Inc. (NYSE:RMD) opened at 77.39 on Friday. The company has a 50-day moving average of $77.07 and a 200 day moving average of $71.57. ResMed Inc. has a 12-month low of $56.59 and a 12-month high of $79.63. The stock has a market capitalization of $10.98 billion, a price-to-earnings ratio of 33.94 and a beta of 0.84.
Several research analysts recently weighed in on RMD shares. J P Morgan Chase & Co cut ResMed from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $72.00 to $71.00 in a research report on Thursday, April 20th. Zacks Investment Research upgraded ResMed from a “sell” rating to a “hold” rating in a research report on Wednesday, April 12th. William Blair reiterated an “outperform” rating on shares of ResMed in a research report on Thursday, April 13th. BMO Capital Markets reiterated a “hold” rating on shares of ResMed in a research report on Friday, May 12th. Finally, Citigroup Inc. cut ResMed from a “buy” rating to a “neutral” rating in a research report on Friday, April 28th. Four investment analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $64.50.
In other news, insider James Hollingshead sold 7,140 shares of the business’s stock in a transaction that occurred on Friday, July 14th. The stock was sold at an average price of $77.43, for a total value of $552,850.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jr. Gregor K. Emmert acquired 424,000 shares of the business’s stock in a transaction dated Wednesday, June 28th. The stock was acquired at an average price of $0.06 per share, with a total value of $25,440.00. Insiders sold 180,261 shares of company stock valued at $13,560,373 over the last 90 days. Company insiders own 1.97% of the company’s stock.
ResMed Company Profile
ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.
Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.